In addition, novel medication of heart failure, such as angiotensin receptor-neprilysin inhibitor (ARNI), has been proven to be associated with improved ejection fraction and prognosis (14); sodium-glucose cotransporter-2 inhibitors (SGLT2i) were effective in reducing cardiovascular and all-cause mortality in patients with heart failure with or without diabetes as well as improving cardiac function and LVEF especially in patients with HFrEF (32–34). Here, SLC5A2 is linked to heart failure.